Insurancenewsnet.com

Lantheus Medical Imaging Presents Promising Results of Latest Safety Studies on DEFINITY® to FDA Advisory Committees

NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Medical Imaging, a worldwide leader in diagnostic medical imaging, completed a successful meeting with the U.S. Food and Drug Administration’s (FDA) ...
Business Wire

New Lantheus Study Finds Significant Survival Benefit for Critically Ill Patients Undergoing Contrast-Enhanced Echocardiography

Transthoracic echocardiography, the most common type of echocardiogram, uses a transducer on a person’s chest to send high frequency ultrasound waves through the chest wall to the heart to create ...
Nasdaq

Lantheus Announces the FDA Approval of DEFINITY® (Perflutren Lipid Microsphere) for Pediatric Patients

BEDFORD, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight ...
Business Wire

Lantheus Medical Imaging Announces FDA Approval of DEFINITY ® Label Update

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Medical Imaging, Inc. (“Lantheus”) today announced U.S. Food and Drug Administration (FDA) approval of an important label update for DEFINITY ® Vial ...
Fierce Healthcare

Lantheus Medical Imaging Announces FDA Accepts for Review DEFINITY® Supplemental New Drug Application for Use in Stress

N. BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that the U.S. Food and Drug Administration (FDA) has accepted ...
Medscape

FDA Puts Boxed Warning on Echo Contrast Agents

October 15, 2007 (Rockville, MD)-As expected, the US FDA has requested that a boxed warning be added to the labeling of two contrast agents used in echocardiography: perflutren liquid microspheres ...
Medscape

FDA Backpedals on Warnings in Echo-Contrast Labeling

May 13, 2008 - The US FDA has approved less ominous and restrictive language for the labeling of the echocardiographic contrast agents perflutren lipid microspheres injectable suspension (Definity, ...
Nasdaq

Lantheus Holdings, Inc. Announces FDA Approval of VIALMIX® RFID Device for DEFINITY®

NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global ...
Seeking Alpha

Lantheus Announces the Approval of DEFINITY® (Perflutren Lipid Microsphere) by China’s NMPA

NORTH BILLERICA, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (LNTH) (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, ...
Business Insider

New study of ultrasound enhancing agents in echocardiography reaffirms safety profile of LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension ...

MONROE TOWNSHIP, N.J., July 15, 2019 /PRNewswire/ -- Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., one of the world's leading companies in the diagnostic imaging business, ...